Four other cases of unknown tumor type, that received either lapatinib, erlotinib (an ErbB1 inhibitor [17]), or sunitib (a multitargeted TK inhibitor [18]) as a second or third line therapy after TMZ, showed PD [3]. This evidence concerns the gene TKT and neoplasm.